Novo Nordisk has entered a collaboration with research institute BioMed X in an effort to regain market position lost to leading competitors in diabetes and obesity treatment. The partnership is focused on improving the low bioavailability of orally administered peptide-based medicines.
ADVERTISEMENT
Tag Archive for: Lilly
Building on the January 2025 ALS drug discovery collaboration with Alchemab Therapeutics, Eli Lilly & Company has secured rights to the first IND-ready program under a US$415m licensing agreement.
Swiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.